<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334242</url>
  </required_header>
  <id_info>
    <org_study_id>LX4211.1-104-NRM</org_study_id>
    <secondary_id>LX4211.104</secondary_id>
    <nct_id>NCT01334242</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the pharmacodynamics of LX4211 relative to
      meals in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary glucose excretion</measure>
    <time_frame>24 hours collection on Day -1 and Days 7-13</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Plasma Glucose</measure>
    <time_frame>Day -1 and Days 7-12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial Glucose</measure>
    <time_frame>Day -1 and Days 7-12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin</measure>
    <time_frame>Day -1 and Days 7-12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucagon-like peptide 1 (total and active)</measure>
    <time_frame>Day -1 and Days 7-12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peptide YY</measure>
    <time_frame>Day -1 and Days 7-12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Day 1 to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood chemistry</measure>
    <time_frame>Day -2, Day 7 and Day 13</time_frame>
    <description>Including albumin, ALP, ALT, AST, total bilirubin, glucose, BUN, calcium, carbon dioxide, chloride, cholesterol and triglycerides, creatinine, magnesium, phosphorus, potassium, sodium, protein, and uric acid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematology</measure>
    <time_frame>Day -2, Day 7 and Day 13</time_frame>
    <description>Including complete blood count with differential, hemoglobin, hematocrit, lymphocyte, and platelet counts.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LX4211</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg of LX4211 administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nonidentical placebo administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Schedule A</intervention_name>
    <description>Dosing 1 hour before breakfast</description>
    <arm_group_label>LX4211</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Schedule B</intervention_name>
    <description>Dosing 0.5 hour before breakfast</description>
    <arm_group_label>LX4211</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Schedule C</intervention_name>
    <description>Dosing immediately before breakfast</description>
    <arm_group_label>LX4211</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Schedule D</intervention_name>
    <description>Dosing immediately before lunch</description>
    <arm_group_label>LX4211</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Schedule E</intervention_name>
    <description>Split dose, dosing 1 hour before breakfast and dinner</description>
    <arm_group_label>LX4211</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 and ≤55 years of age

          -  Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mm
             Hg; diastolic blood pressure, 50-90 mm Hg; heart rate, 50-100 bpm

          -  Body mass index (BMI) ≥18 and ≤35 kg/sq m

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  Use of any medication (prescription, over-the-counter, herbal tea, or supplements)
             within 5 days of dosing

          -  Use of any investigational agent or study treatment within 30 days of Day 1

          -  Use of any protein or antibody-based therapeutic agents within 3 months of Screening

          -  Prior exposure to any SGLT inhibitor

          -  Use of cigarettes or any tobacco products within 6 weeks prior to Screening and while
             participating in the study

          -  History of bariatric surgery or any other gastrointestinal surgery that may induce
             malabsorption

          -  History of any major surgery within 6 months of Screening

          -  History of any hypersensitivity to the inactive components of LX4211

          -  History of renal disease or significantly abnormal kidney function tests

          -  History of hepatic disease or significantly abnormal liver function tests

          -  History of any active infection within 30 days of Day 1

          -  History of alcohol or substance abuse within 2 years prior to Day 1

          -  Positive urine glucose at Screening

          -  Positive pregnancy test at Screening

          -  Inability or difficulty swallowing whole tablets or capsules

          -  Unable or unwilling to communicate or cooperate with the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ikenna Ogbaa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2011</study_first_submitted>
  <study_first_submitted_qc>April 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <last_update_submitted>May 18, 2011</last_update_submitted>
  <last_update_submitted_qc>May 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ikenna Ogbaa, MD - Medical Director</name_title>
    <organization>Lexicon Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Pharmacodynamics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

